Metronidazole: Clinical Overview
Primary Indications
Metronidazole is the drug of choice for trichomoniasis and bacterial vaginosis, with established efficacy for anaerobic infections, though its role has evolved significantly based on infection severity and site. 1
Sexually Transmitted Infections
For trichomoniasis, metronidazole 2 g orally as a single dose achieves 90-95% cure rates and remains the only FDA-approved oral treatment in the United States 1. The alternative regimen is 500 mg twice daily for 7 days. Sex partners must be treated concurrently, and patients should abstain from intercourse until both partners complete therapy and are asymptomatic 1.
For bacterial vaginosis (BV), metronidazole 500 mg orally twice daily for 7 days is effective, though topical azole antifungals are preferred for vulvovaginal candidiasis 2.
Anaerobic Infections
For intra-abdominal infections, metronidazole 500 mg every 8-12 hours intravenously provides adequate anaerobic coverage when combined with appropriate gram-negative agents 3. Recent evidence suggests every 12-hour dosing may be non-inferior to every 8-hour dosing for intra-abdominal infections, though clinical failure requiring broader gram-negative coverage was higher with extended intervals 4.
Clostridioides difficile Infection
Metronidazole is no longer recommended as first-line therapy for C. difficile infection. 5 Vancomycin 125 mg orally four times daily or fidaxomicin 200 mg twice daily for 10 days are strongly preferred for initial episodes. Metronidazole 500 mg orally three times daily for 10 days should only be used when vancomycin or fidaxomicin access is limited, and only for non-severe CDI 5.
For fulminant CDI with hypotension, ileus, or megacolon, use vancomycin 500 mg orally four times daily PLUS intravenous metronidazole 500 mg every 8 hours, particularly when ileus is present 5. The recent ESCMID guidance against IV metronidazole in fulminant CDI is based on limited retrospective data showing only 2.7% non-significant mortality difference, with high heterogeneity 6.
Dosing Regimens
Standard Adult Dosing
- Trichomoniasis: 2 g single dose OR 500 mg twice daily × 7 days 1
- BV in pregnancy (high-risk): 250 mg three times daily × 7 days 1
- Anaerobic infections: 500 mg IV every 8-12 hours 3
- CDI (when necessary): 500 mg three times daily × 10 days 5
Pediatric Dosing
Children under 12 years: 20-30 mg/kg/day divided appropriately 7
Treatment Failure Protocol
For trichomoniasis treatment failure: retreat with 500 mg twice daily × 7 days. If failure persists, use 2 g once daily × 3-5 days. Consult specialists for culture-documented resistance 1, 8.
Contraindications
Metronidazole is absolutely contraindicated in the first trimester of pregnancy for trichomoniasis treatment 9, 2. However, this restriction has evolved: the 1998 CDC guidelines and subsequent evidence indicate metronidazole can be used after the first trimester, with multiple studies showing no consistent teratogenic or mutagenic effects 8.
Additional contraindications:
- Prior hypersensitivity to metronidazole or nitroimidazole derivatives 9
- Concurrent disulfiram use (disulfiram-like reaction with alcohol) 9
Special Populations
Pregnancy considerations:
- First trimester: Contraindicated for trichomoniasis; clindamycin cream preferred for BV 2
- Second/third trimester: Can use 2 g single dose for trichomoniasis or 250 mg three times daily for BV in high-risk patients 1
- Symptomatic pregnant women should be treated to relieve symptoms despite lack of evidence that treating asymptomatic trichomoniasis reduces adverse pregnancy outcomes 8
HIV infection: Use standard dosing regimens; HIV status does not alter treatment 1
Adverse Effects
Common (Mild to Moderate)
- Gastrointestinal: Nausea (12% of patients), vomiting, diarrhea, abdominal cramping, metallic taste 9
- Oral: Furry tongue, glossitis, stomatitis with potential Candida overgrowth 9
Serious (Rare but Important)
Neurological toxicity is the most concerning adverse effect:
- Peripheral neuropathy (numbness, paresthesias) - may be irreversible with prolonged use 9
- Seizures 9
- Encephalopathy, ataxia, confusion, vertigo 9, 10
Patients must immediately discontinue metronidazole and contact their physician if any neurological symptoms develop 9. Avoid repeated or prolonged courses due to cumulative neurotoxicity risk 5.
Other Notable Effects
- Reversible neutropenia and thrombocytopenia 9
- Disulfiram-like reaction with alcohol (abdominal distress, flushing, headache) 9
- Dark urine (benign metabolite, occurs in ~1/100,000 patients) 9
- ECG changes (T-wave flattening) 9
Drug Interactions
Critical interactions with:
- Alcohol: Disulfiram-like reaction 9, 11
- Warfarin: Enhanced anticoagulation 11
- Disulfiram: Additive effects 11
Carcinogenicity Concerns
Metronidazole demonstrates mutagenicity and carcinogenicity in some animal models 12. However, long-term follow-up studies in humans have not revealed increased cancer incidence 12. The drug should only be used for approved indications and not prophylactically 12. Reports of breast and colon cancer in Crohn's disease patients receiving high-dose prolonged metronidazole exist, but causality is unestablished 9.
Clinical Pitfalls
Do not use topical metronidazole gel for trichomoniasis - efficacy <50% due to inadequate urethral/perivaginal gland penetration 8
Avoid metronidazole monotherapy for initial C. difficile infection - vancomycin or fidaxomicin are superior 5
Do not prescribe for non-antimicrobial purposes without strong evidence - veterinary data shows 42% of prescriptions cite putative anti-inflammatory properties without solid evidence base 13
Monitor for cumulative neurotoxicity - particularly with doses of 6-10.4 g every other day for >5-7 days 9
Ensure partner treatment for trichomoniasis - failure to treat partners increases recurrence 1
Resistance is rare but exists - most resistant T. vaginalis strains respond to higher doses; consult specialists for documented resistance 8